ArticleCardiorenal medicine2011
A Case for Early Screening for Diabetic Kidney Disease.
Article in Cardiorenal medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 8 citations in OpenAlex.
- The burden of unrecognised chronic kidney disease in patients with type 2 diabetes at a county hospital clinic in Kenya: implications to care and need for screening.BMC nephrology · 2020Article
- DMP-1 attenuates oxidative stress and inhibits TGF-β activation in rats with diabetic kidney disease.Renal failure · 2017Article
- Diabetic kidney disease and the cardiorenal syndrome: old disease, new perspectives.Endocrinology and metabolism clinics of North America · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic kidney disease (CKD) is a public health dilemma contributing to increasing global morbidity and mortality. There is increasing recognition that early detection and management of CKD is critical in delaying disease progression as well as improving mortality rates. However, kidney disease is a silent process and usually goes undetected until more advanced stages, wherein the opportunity to intervene and improve kidney-related outcome is diminished, since awareness of CKD is low in earlier stages. Herein, we will review the screening and detection strategies for CKD as well as the importance of intervention in early stages to reduce progression and also the burden of CKD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.